A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study to assess the safety,
tolerability, and pharmacokinetics (PK) of escalating single ascending dose (SAD) and
multiple ascending doses (MAD) of ARN-75039 when administered by the oral route in healthy
adult subjects. The SAD portion of the study will enroll approximately 40 subjects for a
total duration of 6 weeks. A cohort of 8 subjects in the SAD portion of the study will be
selected to assess food effect (including relative bioavailability). The MAD portion of the
study will enroll approximately 24 subjects for a total duration of 10 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Arisan Therapeutics, Inc.
Collaborators:
Battelle Memorial Institute The Defense Threat Reduction Agency (DTRA) United States Department of Defense